RUNX1 and cancer: Basheer et al. discovered that the deletion of EZH2 resulted in accelerated disease progression and reduced survival when occurring together with MLL-AF9/AML1-ETO9a suggesting that the presence of EZH2 can function to provide full oncogenic effects; adding another layer of complexity to the multitude of effects EZH2 contributes to cancer [65].